Inotersen, a 2′-O-methoxyethyl (2′-MOE) phosphorothioate antisense oligonucleotide, reduced disease progression and improved quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) in the NEURO-TTR and NEURO-TTR open-label extension (OLE) trials. However, 300 mg/week inotersen treatment was associated with platelet count reductions in several patients. Mean platelet counts in patients in the NEURO-TTR-inotersen group remained ≥140 × 109/L in 50% and ≥100 × 109/L in 80% of the subjects. However, grade 4 thrombocytopenia (<25 × 109/L) occurred in three subjects in NEURO-TTR trial, and one of these suffered a fatal intracranial hemorrhage. The two others were treated successfully with corticosteroids and discontinuation of inotersen. Investigations in a subset of subjects in NEURO-TTR (n = 17 placebo; n = 31 inotersen) and OLE (n = 33) trials ruled out direct myelotoxicity, consumptive coagulopathy, and heparin-induced thrombocytopenia. Antiplatelet immunoglobulin G (IgG) antibodies were detected at baseline in 5 of 31 (16%) inotersen-treated subjects in NEURO-TTR, 4 of whom eventually developed grade 1 or 2 thrombocytopenia while on the drug. In addition, 24 subjects in the same group developed treatment-emergent antiplatelet IgG antibodies, of which 2 developed grade 2, and 3 developed grade 4 thrombocytopenia. Antiplatelet IgG antibodies in two of the three grade 4 thrombocytopenia subjects targeted GPIIb/IIIa. Plasma cytokines previously implicated in immune dysregulation, such as interleukin (IL)-23 and a proliferation-inducing ligand (APRIL) were often above the normal range at baseline. Collectively, these findings suggest an underlying immunologic dysregulation predisposing some individuals to immune-mediated thrombocytopenia during inotersen treatment.
Get full access to this article
View all access options for this article.
References
1.
BensonMD. (2017). Transthyretin amyloidosis: a little history of hereditary amyloidosis. Amyloid, 24:76–77.
2.
AnderssonR. (1976). Familial amyloidosis with polyneuropathy. A clinical study based on patients living in northern Sweden. Acta Med Scand Suppl, 590:1–64.
3.
BensonMD, Kluve-BeckermanB, LiepnieksJJ, MurrellJR, HanesD and UemichiT. (1996). Metabolism of amyloid proteins. Ciba Found Symp 199:104–113; discussion. 113–118.
4.
ConnellyS, ChoiS, JohnsonSM, KellyJW and WilsonIA. (2010). Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Curr Opin Struct Biol, 20:54–62.
5.
GertzMA. (2017). Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. Am J Manag Care, 23:S107–S112.
6.
KeamSJ. (2018). Inotersen: first global approval. Drugs, 78:1371–1376.
7.
AckermannEJ, GuoS, BensonMD, BootenS, FreierS, HughesSG, KimTW, Jesse KwohT, MatsonJ, et al. (2016). Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides. Amyloid, 23:148–157.
8.
BensonMD, Waddington-CruzM, BerkJL, PolydefkisM, DyckPJ, WangAK, Plante-BordeneuveV, BarrosoFA, MerliniG, et al. (2018). Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med, 379:22–31.
9.
JaaxME, KrauelK, MarschallT, BrandtS, GanslerJ, FurllB, AppelB, FischerS, BlockS, et al. (2013). Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4. Blood, 122:272–281.
10.
AsterRH, CurtisBR, McfarlandJG and BougieDW. (2009). Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management. J Thromb Haemost, 7:911–918.
11.
SchwartzRS and StollarBD. (1985). Origins of anti-DNA autoantibodies. J Clin Invest, 75:321–327.
12.
DenommeGA, KeltonJG and BellDA. (1992). The production of human monoclonal antiplatelet auto-antibodies derived from human lymphocytes of normal origin: reactivity to DNA, anionic phospholipids and platelet proteins. Br J Haematol, 82:99–106.
13.
TrioloG, PalumboAA, GiardinaE, DaviG and TrioloG. (1994). Anti platelet property of anti-single-stranded DNA antibodies in type 1 (insulin-dependent) diabetes mellitus. Diabetes Res, 26:79–87.
14.
VincentFB, Saulep-EastonD, FiggettWA, FairfaxKA, MackayF. (2013). The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev, 24:203–215.
15.
Page-MccawA, EwaldAJ and WerbZ. (2007). Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol, 8:221–233.
16.
BroudyVC. (1997). Stem cell factor and hematopoiesis. Blood, 90:1345–1364.
17.
GreenbergDA and JinK. (2005). From angiogenesis to neuropathology. Nature, 438:954–959.
18.
ZhuB, XuD, DengX, ChenQ, HuangY, PengH, LiY, JiaB, ThoresonWB, et al. (2012). CXCL12 enhances human neural progenitor cell survival through a CXCR7- and CXCR4-mediated endocytotic signaling pathway. Stem Cells, 30:2571–2583.
19.
LubbertsE. (2008). IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis? Cytokine, 41:84–91.
20.
QianC, JiangT, ZhangW, RenC, WangQ, QinQ, ChenJ, DengA and ZhongR. (2013). Increased IL-23 and IL-17 expression by peripheral blood cells of patients with primary biliary cirrhosis. Cytokine, 64:172–180.
21.
FransenK, Van SommerenS, WestraHJ, VeenstraM, LambertsLE, ModdermanR, DijkstraG, FuJ, WijmengaC, et al. (2014). Correlation of genetic risk and messenger RNA expression in a Th17/IL23 pathway analysis in inflammatory bowel disease. Inflamm Bowel Dis, 20:777–782.
22.
YeX, ZhangL, WangH, ChenY, ZhangW, ZhuR, FangC, DengA and Qian.B (2015). The role of IL-23/Th17 pathway in patients with primary immune thrombocytopenia. PLoS One, 10:e0117704.
23.
BuchwaldD, WenerMH, PearlmanT and KithP. (1997). Markers of inflammation and immune activation in chronic fatigue and chronic fatigue syndrome. J Rheumatol, 24:372–376.
24.
YuRZ, GrundyJS and GearyRS. (2013). Clinical pharmacokinetics of second generation antisense oligonucleotides. Expert Opin Drug Metab Toxicol, 9:169–182.
25.
NarayananPK, ShenL, CurtisBR, BourdonM, NolanJP, ZhouF, ChristianB, GuptaS, SchaubhutJL, et al. (2018). Investigation into the mechanism(s) that leads to platelet decreases in cynomolgus monkeys during administration of ISIS-104838, a 2′-MOE-modified antisense oligonucleotide. Toxicol Sci, 164:kfy119.
26.
TaskerL and Marshall-ClarkeS. (2003). Functional responses of human neonatal B lymphocytes to antigen receptor cross-linking and CpG DNA. Clin Exp Immunol, 134:409–419.
27.
HoffmanR, BenzEJ, SilbersteinLE, HeslopH, JeffreyW and AnastasiJ. (2018). Hematology Basic Principles and Practice. Elsevier, Philadelphia.
28.
LitvackML and PalaniyarN. (2010). Review: soluble innate immune pattern-recognition proteins for clearing dying cells and cellular components: implications on exacerbating or resolving inflammation. Innate Immun, 16:191–200.
29.
ShenL, Frazer-AbelA, ReynoldsPR, GiclasPC, ChappellA, PangburnMK, YounisH and HenrySP. (2014). Mechanistic understanding for the greater sensitivity of monkeys to antisense oligonucleotide-mediated complement activation compared with humans. J Pharmacol Exp Ther, 351:709–717.
30.
SennJJ, BurelS and HenrySP. (2005). Non-CpG-containing antisense 2′-methoxyethyl oligonucleotides activate a proinflammatory response independent of Toll-like receptor 9 or myeloid differentiation factor 88. J Pharmacol Exp Ther, 314:972–979.
31.
OgdenCA, KowalewskiR, PengY, MontenegroV and ElkonKB. (2005). IGM is required for efficient complement mediated phagocytosis of apoptotic cells in vivo. Autoimmunity, 38:259–264.
32.
SakamotoA, OdaY, AdachiT, TamiyaS, MatsudaS, TanakaK, IwamotoY and TsuneyoshiM. (2001). H-ras oncogene mutation in dedifferentiated liposarcoma. Polymerase chain reaction-restriction fragment length polymorphism analysis. Am J Clin Pathol, 115:235–242.
33.
ShibuyaA, SakamotoN, ShimizuY, ShibuyaK, OsawaM, HiroyamaT, EyreHJ, SutherlandGR, EndoY, et al. (2000). Fc alpha/mu receptor mediates endocytosis of IgM-coated microbes. Nat Immunol, 1:441–446.
34.
GriffinDO, HolodickNE, and RothsteinTL. (2011). Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+ CD27+ CD43+ CD70. J Exp Med, 208:67–80.
35.
GenestierL, TaillardetM, MondiereP, GheitH, BellaC, and DefranceT. (2007). TLR agonists selectively promote terminal plasma cell differentiation of B cell subsets specialized in thymus-independent responses. J Immunol, 178:7779–7786.
36.
JiangW, LedermanMM, HardingCV, RodriguezB, MohnerRJ, and SiegSF. (2007). TLR9 stimulation drives naive B cells to proliferate and to attain enhanced antigen presenting function. Eur J Immunol, 37:2205–2213.
37.
KuboT, UchidaY, WatanabeY, AbeM, NakamuraA, OnoM, AkiraS, and TakaiT. (2009). Augmented TLR9-induced Btk activation in PIR-B-deficient B-1 cells provokes excessive autoantibody production and autoimmunity. J Exp Med, 206:1971–1982.
38.
PazS, HsiaoJ, CauntayP, SorianoA, BaiL, MachemerT, XiaoX, GuoS, HungG, et al. (2017). The Distinct and cooperative roles of toll-like receptor 9 and receptor for advanced glycation end products in modulating in vivo inflammatory responses to select CpG and non-CpG oligonucleotides. Nucleic Acid Ther, 27:272–284.
39.
ChouMY, FogelstrandL, HartvigsenK, HansenLF, WoelkersD, ShawPX, ChoiJ, PerkmannT, BackhedF, et al. (2009). Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. J Clin Invest, 119:1335–1349.
40.
ArnoldDM, KukaswadiaS, NaziI, EsmailA, DewarL, SmithJW, WarkentinTE, and KeltonG. (2013). A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia. J Thromb Haemost, 11:169–176.
41.
VrbenskyJR, MooreJE, ArnoldDM, SmithJW, KeltonJG, and NazyI. (2019). The sensitivity and specificity of platelet autoantibody testing in immune thrombocytopenia: a systematic review and meta-analysis of a diagnostic test. J Thromb Haemost, 17:787–794.
42.
BiburgerM, AschermannS, LuxA, and NimmerjahnF. (2010). The role of Fcgamma receptors in murine autoimmune thrombocytopenia. Ann Hematol 89 Suppl, 1:25–30.
43.
CrookeST, BakerBF, KwohTJ, ChengW, SchulzDJ, XiaS, SalgadoN, BuiHH, HartCE, et al. (2016). Integrated safety assessment of 2′-O-Methoxyethyl chimeric antisense oligonucleotides in nonhuman primates and healthy human volunteers. Mol Ther, 24:1771–1782.
44.
ChatterjeeM, Von Ungern-SternbergSN, SeizerP, SchlegelF, ButtcherM, SindhuNA, MullerS, MackA, and Gawaz.M (2015). Platelet-derived CXCL12 regulates monocyte function, survival, differentiation into macrophages and foam cells through differential involvement of CXCR4-CXCR7. Cell Death Dis, 6:e1989.
45.
LuoX, WangX, XiaZ, ChungSK, and CheungCW. (2016). CXCL12/CXCR4 axis: an emerging neuromodulator in pathological pain. Rev Neurosci, 27:83–92.
46.
GuyonA. (2014). CXCL12 chemokine and its receptors as major players in the interactions between immune and nervous systems. Front Cell Neurosci, 8:65.
47.
DhandapaniKM, WadeFM, WakadeC, MaheshVB, and BrannDW. (2005). Neuroprotection by stem cell factor in rat cortical neurons involves AKT and NFkappaB. J Neurochem, 95:9–19.
48.
SousaMM, Du YanS, FernandesR, GuimaraesA, SternD, and SaraivaMJ. (2001). Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways. J Neurosci, 21:7576–7586.
49.
WeldonDT, RogersSD, GhilardiJR, FinkeMP, ClearyJP, O'hareE, EslerWP, MaggioJE, and MantyhPW. (1998). Fibrillar beta-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J Neurosci, 18:2161–2173.
50.
FarfaraD, LifshitzV, and FrenkelD. (2008). Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease. J Cell Mol Med, 12:762–780.
51.
GoncalvesNP, VieiraP, SaraivaMJ. (2014). Interleukin-1 signaling pathway as a therapeutic target in transthyretin amyloidosis. Amyloid, 21:175–184.
52.
TofarisGK, PattersonPH, JessenKR, and MirskyR. (2002). Denervated Schwann cells attract macrophages by secretion of leukemia inhibitory factor (LIF) and monocyte chemoattractant protein-1 in a process regulated by interleukin-6 and LIF. J Neurosci, 22:6696–6703.
53.
SchmidtAM, YanSD, YanSF, and SternDM. (2001). The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest, 108:949–955.
54.
SousaMM, CardosoI, FernandesR, GuimaraesA, and SaraivaMJ. (2001). Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am J Pathol, 159:1993–2000.
55.
KurianSM, NovaisM, WhisenantT, GelbartT, BuxbaumJN, KellyJW, CoelhoT, and SalomonDR. (2016). Peripheral blood cell gene expression diagnostic for identifying symptomatic transthyretin amyloidosis patients: male and female specific signatures. Theranostics, 6:1792–1809.
56.
VillaltaSA, RosenbergAS, BluestoneJA. (2015). The immune system in Duchenne muscular dystrophy: friend or foe. Rare Dis, 3:e1010966.
57.
HeB, QiaoX, and CeruttiA. (2004). CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. J Immunol, 173:4479–4491.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
